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ABSTRACT 
Severe haemorrhage can lead to global ischaemia and haemorrhagic shock (HS), resulting in multiple 
organ failure (MOF) and death. Restoration of blood flow and reoxygenation is associated with an 
exacerbation of tissue injury and inflammatory response. The neuronal nitric oxide synthase (nNOS) 
has been implicated in vascular collapse and systemic inflammation of septic shock; however the 
role of nNOS in HS is poorly understood. The aim of this study is to evaluate the role of nNOS in the 
MOF associated with HS. 
Rats were subjected to HS under anaesthesia. Mean arterial pressure was reduced to 30 mmHg for 90 
min, followed by resuscitation with shed blood. Rats were randomly treated with 2 chemically 
distinct nNOS inhibitors (ARL 17477 1 mg/kg and 7-nitroindazol 5 mg/kg) or vehicle upon 
resuscitation. Four hours later, parameters of organ injury and dysfunction were assessed. 
HS was associated with MOF development. Inhibition of nNOS activity at resuscitation protected 
rats against the MOF and vascular dysfunction. In addition, treatment of HS-rats with nNOS 
inhibitors attenuated neutrophil infiltration into target organs and decreased the activation of NF- B, 
iNOS expression, NO production and nitrosylation of proteins. Furthermore, nNOS inhibition also 
reduced the levels of pro-inflammatory cytokines TNF- -6 in HS-rats. 
In conclusion, two distinct inhibitors of nNOS activity reduced the MOF, vascular dysfunction and 
the systemic inflammation associated with HS. Thus, nNOS inhibitors may be useful as an adjunct 
therapy before fluids and blood administration in HS patients in order to avoid the MOF associated 
with reperfusion injury during resuscitation. 
 
Keywords: nitric oxide, nNOS, iNOS, nitrosylation, organ injury and dysfunction, haemorrhage, 
resuscitation.  
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INTRODUCTION 
Trauma is the main cause of death for people under 35 years, with more than 5 million deaths 
every year around the world. Severe haemorrhage associated with trauma can lead to a state of global 
ischaemia and haemorrhagic shock (HS), resulting in multiple organ failure (MOF) and death. 
Unfortunately, the chances for survival after trauma have not significantly improved for decades (1). 
Prehospital HS treatment should be focused on the maintenance of adequate mean arterial pressure 
(MAP) along with organ perfusion until arrival at the hospital. Vasopressors may also be required to 
maintained tissue perfusion when the fluid resuscitation does not achieve the expected goal (2).  
HS is one of the most common types of shock and causes an ischaemia-reperfusion-type 
injury (3). The restriction of blood supply to organs after bleeding causes tissue hypoxia (ischaemia), 
and the restoration of blood flow and reoxygenation is associated with an exacerbation of tissue 
injury and a profound inflammatory response (reperfusion injury) (4). The excessive generation of 
free radicals [such as superoxide anion and nitric oxide (NO)] play a key role in post-ischaemic 
tissue injury (5).  
There is now good evidence that an enhanced formation of NO contributes to the 
pathophysiology of septic and haemorrhagic shock. Most studies indicate that the expression of 
inducible NO synthase (iNOS) is the key source of the observed enhanced NO formation (6-9). 
However, there is recent evidence that the activation of the neuronal isoform of NOS (nNOS) may 
also play an important role in the pathogenesis of the systemic inflammatory response in sepsis (10-
14). Most notably, activation of nNOS importantly contributes to the vascular dysfunction in sepsis 
(14) and sepsis in nNOS-gene knockout animals is associated with the reduced release of pro-
inflammatory cytokines as well as reduced oxidative and nitrosative stress (12, 15). However, we 
know very little about the roles of nNOS in the vascular decompensation, organ injury/dysfunction 
and inflammation associated with HS.  
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Therefore, the aim of the present study was to investigate the role of nNOS in the organ 
injury and dysfunction associated with a relevant model of HS in the rat. As both specificity and 
selectivity of any drug may be an issue especially when using inhibitors of NOS, we have compared 
the effects of 2 chemically distinct and potent nNOS inhibitors, namely ARL 17477 (ARL) and 7-
nitroindazol (7NI). ARL is 17 times more selective for nNOS than eNOS (IC50 are 1 and 17 M, 
respectively; 16). In vitro, 7NI is an equipotent inhibitor of all isoforms of NOS, but in vivo 7NI 
exhibits a marked selectivity for the nNOS, possibly as a result of differential cellular uptake (17). 
Our results show that the nNOS inhibition at the onset of resuscitation protects rats against the MOF 
and vascular dysfunction associated with HS thorough the attenuation of NF- B activation and 
consequent reduction of NF-  -dependent proteins (such as iNOS and pro-inflammatory cytokines), 




The animal protocols used in this study were approved by the Animal Welfare Ethics Review 
Board (AWERB) of Queen Mary University of London (PPL: 70/7348) in accordance with the 
derivatives of Home Office guidance on Operation of Animals (Scientific Procedures Act 1986) 
Animals of the National Research Council. 
Haemorrhagic Shock 
This study was carried out on male Wistar rats (Charles River Ltd, Margate, UK) weighing 
230 g to 280 g. The animals were housed in a temperature-controlled environment with a 12 h 
light/dark cycle and received a standard diet and water ad libitum. Haemorrhagic shock (HS) was 
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performed as previously described (18). Briefly, rats were anaesthetized with sodium thiopentone 
(120 mg/kg i.p., maintained using 10 mg/kg i.v.) and cannulation of trachea, bladder, jugular vein, 
and femoral and carotid arteries were performed. Body temperature was monitored by a rectal 
thermometer (36 ± 0.5 oC) by means of a homoeothermic blanket system (Harvard Apparatus, 
Natick, MA). Blood was withdrawn through carotid artery in a rate of 1 mL/min to achieve a mean 
arterial pressure (MAP) of 30 ± 2 mmHg, which was recorder through the femoral artery with a 
pressure transducer coupled to a PowerLab 8/30 (AD Instruments Pty Ltd., Castle Hill, Australia). 
The MAP was maintained at 30 ± 2 mmHg either by further withdrawal of blood during the 
compensation phase or administration of shed blood during the decompensation phase. The total 
volume of shed blood was 9,46 ± 1,40; 8,72 ± 0,44 and 9,72 ± 1,40 mL for HS+Vehicle, HS+ARL 
and HS+7NI, respectively (p>0.05). The volume of re-infused blood for maintenance of MAP at 30 
± 2 mmHg was 2,37 ± 0,54; 1,69 ± 0,69 and 1,79 ± 0,43 mL for HS+Vehicle, HS+ARL and 
HS+7NI, respectively (p>0.05). After 90 min of initiation of haemorrhage or when 25% of the shed 
blood had to be re-injected to sustain MAP at 30 ± 2 mmHg, resuscitation was performed over a 
period of 5 min with the remained shed blood mixed with 100 IU/mL heparinized saline. The same 
volume of blood re-infused for maintenance of MAP (see above) was replaced by  on 
resuscitation. In addition, 1 h after the resuscitation with the blood, a
was started (1.5 mL/kg/h; i.v.) and this fluid replacement was maintained throughout the whole 
experiment. Two hours after onset of resuscitation, a dose-response curve for norepinephrine (NE; 1, 
3 and 10 nmol/kg) was performed in all experimental groups. Four hours after resuscitation, blood 
was obtained for measurement of lactate (Accutrend Plus Meter, Roche Diagnostics, West Sussex, 
UK), serum cytokines and assessment of organ injury. Also, at this time, kidney and liver were 
harvested for further analysis. Blood samples were centrifuged to separate serum from which 
creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and creatine kinase 
(CK) were measured within 24 h (IDEXX Laboratories Ltd, West Yorkshire, UK). The last 3 h urine 
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was obtained for the estimation of the creatinine clearance. Sham-operated rats were used as control 
and underwent identical surgical procedures but without haemorrhage or resuscitation. 
Experimental design 
Rats were subjected to surgery and randomly divided into the following 6 groups (n = 8-10 
per group): (i) sham + vehicle; (ii) sham + ARL 17477 (ARL; 1 mg/kg); (iii) sham + 7-nitroindazol 
(7NI; 5 mg/kg); (iv) HS + vehicle; (v) HS + ARL (1 mg/kg) and (vi) HS + 7NI (5 mg/kg). ARL was 
dissolved in PBS and 7NI was dissolved in 10% DMSO. Control groups (sham and HS) were 
performed with 10% DMSO or PBS, and since no difference was found between them, they were 
grouped [sham + vehicle (PBS n=4 and 10% DMSO n=4) and HS + vehicle (PBS n=5 and 10% 
DMSO n=5)]. The doses of 7NI and ARL used in our study were based on previous studies that have 
been shown to inhibit nNOS activity in vivo (14, 16, 19; see also introduction).  
Western blotting 
Western blotting was performed as previously described (18). Briefly, kidney (cortex + 
medulla) and liver samples were homogenized and centrifuged. After electrophoresis, the proteins 
were transferred to a polyvinyldenediflouoride (PVDF) membrane, which was incubated with a 
primary antibody [mouse anti-total I - 32/36 (1:1000); rabbit anti-
NF- -iNOS (1:200); rabbit anti-nNOS (1:1000)]. Membranes were 
incubated with a secondary antibody conjugated with horseradish peroxidase (1:2000) and developed 
with ECL detection system. The membranes were s -actin monoclonal 
antibody (1:5000) and subsequently with an anti-mouse antibody (1:10000) to assess gel-loading 
homogeneity. The immunoreactive bands were visualized by autoradiography and the densitometric 
analysis was performed using Gel Pro Analyzer 4.5, 2000 software (Media Cybernetics, Silver 
Spring, MD, USA).  
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Nitrite and nitrate (NOx)  
Briefly, nitrate was converted to nitrite using nitrate reductase in the presence of co-factors. 
The total nitrite in plasma was assayed by adding Griess reagent [0.05% (wt/vol) 
naphthalethylenediamine dihydrochloride and 0.5% (wt/vol) sulphanilamide in 2.5% (vol/vol) 
phosphoric acid] to each sample and read at 550 nm. NOx concentration, as nitric oxide synthesis 
estimation, was calculated by comparison with standard solution of sodium nitrate prepared in water.  
Immunohistochemistry for nitrotyrosine and myeloperoxidase (MPO) 
Briefly, 4 µm sections of kidney and liver samples were obtained. For nitrotyrosine, the 
sections were blocked with PBS / 1% BSA (PBA) for 1 h and then incubated with 2% goat serum in 
PBA for 30 min. For myeloperoxidase, the sections were blocked with 10% goat serum for 15 min. 
The slides were then incubated with rabbit anti-nitrotyrosine antibody (1:2000; Merck Millipore, 
Darmstadt, Germany) or with rabbit anti-myeloperoxidase antibody (1:25; Cat# ab9535, Abcam, 
Cambridge, UK) and then incubated with labelled polymer-HRP antibody (Dako EnVision+ System-
HRP-DAB, K4010). DAB chromogen solution was used and a counter-staining was performed with 
Harris haematoxylin. Images were acquired using NanoZoomer Digital Pathology Scanner 
(Hamamatsu Photonics K.K., Japan) and analysed using the NDP Viewer software. The relative 
quantification of nitrotyrosine immunostaining was achieved through densitometry analysis using 
NIH ImageJ 1.36 imaging software (NIH, Bethesda, MD, USA) and it is expressed as arbitrary units. 
The number of MPO positive cells was counted in 10 randomly selected fields (x 400) in a double-
blinded manner. 
Cytokines determination 
Serum cytokines TNF-  and IL-6 were determined using commercial immunoassay kits 
(R&D Systems, Minneapolis, MN) according to the manufacturer protocol.  
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Reagents 
ARL 17477 dihydrochloride was purchased from Tocris Bioscience (R&D systems Europe, 
Abingdon, UK). Unless otherwise stated, all compounds used in this study were purchased from 
Sigma-Aldrich Company Ltd (Poole, Dorset, UK). All stock solutions were prepared using 
nonpyrogenic PBS
assay kit and SuperBlock blocking buffer were from Thermo Fisher Scientific Inc. (Rockford, IL, 
USA). Antibodies (anti- anti- 32/36, anti-NF- , anti-iNOS and anti-nNOS) 
were from Cell Signalling Technology Inc. (Beverly, MA, USA), anti-nitrotyrosine was from Merck 
Millipore (Darmstadt, Germany) and anti-myeloperoxidase was from Abcam (Cambridge, UK).  
Data analysis 
All values are expressed as mean ± SEM. Statistical analysis was carried out using Graph 
Prism 5.03 (Graph Pad Software, San Diego, CA). Data were assessed by one or two-way ANOVA 
p value of less than 0.05 was considered to be significant.  
 
RESULTS 
Inhibition of nNOS protects against organ injury and dysfunction associated with HS 
When compared to sham-operated rats, HS-rats exhibited decreased increased levels of serum 
creatinine (Figure 1A) and a significant decrease in creatinine clearance (Figure 1B). HS-rats also 
had elevated plasma concentrations of aspartate aminotransferase (AST; Figure 1C), alanine 
aminotransferase (ALT; Figure 1D) and creatine kinase (CK; Figure 1E) indicating liver and 
muscular injury, respectively. When compared to sham-operated rats, HS-rats treated with vehicle 
also had elevated concentrations of blood lactate (Figure 1F), indicating global tissue hypoxia. The 
treatment of HS-rats with the nNOS inhibitors ARL or 7NI, significantly attenuated the plasma 
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creatinine increase and the reduction on creatinine clearance, and the liver and muscle injury 
associated with HS. The nNOS inhibitors ARL and 7NI also attenuated tissue hypoxia, as observed 
by lower lactate levels when compared to HS vehicle group. The treatment of sham-rats with nNOS 
inhibitors had no significant effect when compared to sham vehicle group (Figure 1).  
Inhibition of nNOS prevents circulatory failure and vasoconstrictor hyporeactivity associated with 
HS 
When compared to sham-operated rats (open circles), HS-rats treated with vehicle (closed 
squares) exhibited a significant reduction in MAP after resuscitation (Figure 2A). Administration of 
ARL at resuscitation failed to attenuate the reduction in MAP caused by HS (closed triangle and 
open diamond, respectively). In contrast, inhibition of nNOS with 7NI at resuscitation totally 
impaired the development of circulatory failure in HS rats (closed diamond). The MAP from sham 
animals treated with ARL or 7NI were not different from sham vehicle group (data not shown). 
In addition to the circulatory failure, we have also investigated the vasoconstrictor reactivity 
to NE. Two hours after resuscitation, HS-rats developed a substantial reduction in NE (3 and 10 
nmol/kg) response (Figure 2B; black bars) when compared with sham rats (open bars). The treatment 
of HS-rats at resuscitation with ARL or 7NI was able to prevent the development of NE 
hyporeactivity significantly (Figure 2B). The administration of NE in sham rats treated with ARL or 
7NI had no significant effect when compared to sham vehicle group (data not shown). 
Inhibition of nNOS reduces neutrophil accumulation associated with HS 
As both ARL and 7NI reduced the organ injury associated with HS, we investigated the 
mechanisms involved in organ protection in renal and liver biopsies. When compared with sham rats, 
HS-rats treated with vehicle showed an increase in MPO positive cells in kidney and liver, indicating 
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an accumulation of neutrophils in these tissues. The administration of ARL or 7NI significantly 
decreased neutrophils accumulation in both organs (Figure 3). 
Inhibition of nNOS attenuates NF-  
When compared with sham-operated rats, kidney (Figures 4A and C) and liver (Figures 4B 
and D) from rats subjected to HS exhibited a significant increase in the phosphorylation of 
Ser32/36 (Figures 4A and B) and translocation of the NF- to the nucleus (Figures 4C 
and D). The treatment of HS-rats with ARL or 7NI attenuated the p
Ser32/36 and translocation of the NF-
and liver (Figure 4). Treatment of sham animals with both nNOS inhibitors caused no difference in 
NF- B activation when compared with sham vehicle group (data not shown).  
Inhibition of nNOS attenuates iNOS expression and NOx production associated with HS 
As iNOS is a NF- B-dependent gene, and it is also involved in the development of 
circulatory failure and hyporeactivity to vasoconstrictors associated with HS and sepsis, we have also 
investigated the effects of nNOS inhibition on later iNOS expression and NOx production. When 
compared with sham-operated rats, kidney and liver from HS-rats exhibited a significant increase in 
iNOS expression (Figures 5A and B, respectively), and an increase in serum NOx production (Figure 
6). The treatment of HS-rats with nNOS inhibitors ARL or 7NI attenuated the increase of iNOS 
expression associated with HS (Figure 5A and B), as well as NOx production (Figure 6). In contrast, 
no difference among the groups in nNOS expression was noticed in kidney or liver (Figures 5C and 
D).  
Inhibition of nNOS attenuates nitrosylation of proteins associated with HS 
As we observed a reduction in iNOS expression as well as in NOx production in HS-rats 
treated with nNOS inhibitors, we determined the tyrosine nitration in kidney and liver tissue by 
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immunohistochemistry. When compared with sham-operated rats (Figures 7A and H), kidney and 
liver of HS-rats exhibited a marked staining for nitrotyrosine (Figures 7B and I, respectively). 
Treatment of HS-rats with ARL or 7NI attenuated the staining for nitrotyrosine both in kidney and 
liver (Figures 7G and N). No difference in nitrotyrosine staining was noticed between sham animals 
treated with vehicle or with nNOS inhibitors (Figure 7).  
Inhibition of nNOS attenuates pro-inflammatory cytokines production associated with HS 
When compared with sham-operated rats, the pro-inflammatory cytokines TNF-
and IL-6 (Figure 8B) were significantly increased in the serum of HS-rats treated with vehicle. The 
treatment of HS-rats with ARL or 7NI attenuated the production of both cytokines. No significant 




The main findings of the present study are that the inhibition of nNOS (with two potent 
inhibitors of nNOS) at resuscitation protected rats against the vascular decompensation and the 
multiple organ injury/dysfunction associated with HS. Inhibition of nNOS activity was associated 
with: (i) reduction of neutrophil migration to organs, (ii) attenuation of NF- activation, (iii) 
reduction of NF- -dependent protein expression (including iNOS and the pro-inflammatory 
cytokines TNF- and IL-6) and (iv) attenuation of protein nitrosylation by NO-derived species.  
The vascular decompensation in HS is associated with an enhanced formation of NO (6) and 
the induction of iNOS induced by preconditioning with LPS aggravates the organ dysfunction 
associated with HS (18). Non-selective inhibition of NOS preserves myocardial function (20) and 
increases survival in HS (21), while the selective inhibition of iNOS attenuates circulatory failure 
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and the organ injury/dysfunction associated with HS (7, 22). Although iNOS has been claimed to be 
the main source of NO production, the neuronal isoform of NOS may have a more prominent role in 
sepsis and HS. The nNOS-derived NO plays a key role in the pathophysiology of lung injury (10), 
MOF (11) and vascular dysfunction (14) induced by sepsis.  
Our data show that nNOS inhibition at the onset of resuscitation attenuates the organ injury 
and dysfunction associated with HS. To our knowledge, this is the first study that investigates the 
role of nNOS in MOF associated with this critical condition. In addition, as hypotension and 
hyporeactivity to vasoconstrictors are strongly associated with NO production (8, 9, 23), the 
inhibition of nNOS also impaired the vascular hyporeactivity associated with HS. This result is in 
accordance with previous studies that show that nNOS has an important role in the vascular 
dysfunction in sepsis and endotoxemia (12, 14).   
To investigate the mechanisms by which nNOS inhibition afforded organ protection in HS, 
we first evaluated the role of the neutrophils in the main organs affected by HS (kidney and liver). 
Neutrophils play an important role in the pathogenesis of MOF after HS, and cause direct local 
cytotoxic cellular effects through degranulation and release of substances such as myeloperoxidase, 
reactive oxygen species and cytokines. HS-rats have increased number of neutrophils (MPO+ cells) 
in kidney and liver tissues. Interestingly, both nNOS inhibitors (ARL and 7NI) decreased the number 
of neutrophils in both shock organs. This was indeed a curious finding as NO inhibits rolling and 
adhesion of neutrophils in inflammation and sepsis (24). However, this matter is still unresolved as 
iNOS knockout animals or animals treated with the different NOS inhibitors show a reduction in 
neutrophil migration to inflammatory sites in several models of inflammation, including HS (22, 25). 
Indeed, the role of NO on neutrophil influx seems to be dependent on the tissue and also on the 
stimulus (25). 
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It is described that, in vitro, NO donors can inhibit NOS activity (26) and NO derived from 
the endothelial isoforms of NOS modulates the expression of iNOS in macrophages (27) in a NF- B-
dependent way (28). Moreover, Duma and colleagues showed that nNOS knockout animals or wild-
type animals treated with a nNOS inhibitor, when subjected to CLP model, exhibited reduction of the 
expression of iNOS and lower NO production than CLP control animals (12). Also, nNOS-derived 
NO is shown to act as signalling agent for iNOS expression in vascular smooth muscle cells (29). 
With this in mind, we have also investigated the role of nNOS inhibition on iNOS expression in HS-
rats. Our data clearly show that nNOS-derived NO is able to modulate iNOS expression in HS in a 
NF- B-dependent manner. According to our data, both nNOS inhibitors attenuated the 
phosphorylation of  and NF- B activation. Indeed, the inhibition of NF-
be benefit in HS, attenuating the organ failure and dysfunction (30). The reduction of NF- B 
activation led to the attenuation of iNOS expression, while the expression of nNOS (as expected) 
was unchanged in any of the animal groups investigated. The systemic levels of NOx, the stable 
metabolites of NO, were increased in HS-rats and were attenuated in rats treated with both nNOS 
inhibitors. It is unclear whether the reduction of NOx is due to inhibition of nNOS activity or 
prevention of iNOS expression by the nNOS inhibitors used.  
Indeed, NO can react with superoxide anion to form peroxynitrite, which may nitrate proteins 
causing cytotoxicity and interfering with signal transduction mechanisms. The detection of 
nitrotyrosine represents a reliable marker of nitrosative stress and tissue injury (31). Not surprisingly, 
nitration of proteins by peroxynitrite is linked with organ injury and dysfunction in critical conditions 
associated with high production of NO, such as sepsis and HS (5, 7). Also, peroxynitrite scavengers 
decrease protein nitration and improve renal function in sepsis (32). Our data confirm that the 
formation of peroxynitrite in HS-rats is increased, causing protein nitration and consequently organ 
injury and dysfunction. We show that the attenuation of nNOS activity and iNOS expression (and the 
subsequent decreased NO formation) attenuated peroxynitrite and consequently the nitration of 
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proteins in liver and kidney from HS-rats. We do believe that the reduction of nitrotyrosine in the 
tissues may importantly contribute to the organ protection observed in HS-rats treated with nNOS 
inhibitors.  
The attenuation of NF- o-inflammatory cytokines 
formation (TNF- -6) in HS-rats, which may also account for the beneficial effect on organ 
injury and dysfunction. Elevated serum IL-6 concentrations predict the development of organ failure 
in trauma-haemorrhage patients and increases in TNF-
organ injury and death followed trauma (30, 33, 34). This is an interesting finding, as the beneficial 
effects of nNOS inhibition in HS were clearly beyond iNOS modulation. 
Our study has some limitations that need to be considered. The HS model that we used in this 
study is a very acute model of severe HS, which leads to MOF and systemic inflammation within a 
few hours of the onset of resuscitation. Although acute, at this time point (4 h after resuscitation) we 
have observed organ dysfunction, a substantial activation of the NF- enhanced 
expression of iNOS and formation of pro-inflammatory cytokines. However, although effective in 
this acute setting, we cannot conclude that nNOS inhibition will have the same beneficial effect in an 
animal model with long-term resuscitation periods and/or affect mortality.   
Moreover, it could be argued that the observed effects of nNOS inhibitors are due to non-
specific effects. We cannot exclude the possibility that the inhibitors used in this study have exerted 
their beneficial effects through off-target effects not related to nNOS-inhibition, such as eNOS 
inhibition, especially with the use of 7NI. We regard this as the main limitation of our work, as we 
were not able to perform this study in knockout animals. In vitro, 7NI is equipotent as an inhibitor of 
both nNOS and eNOS. On the other hand, in vivo, evidences suggest 7NI is more selective for nNOS 
(17, 35). However, there are some controversies (36), and we cannot exclude that 7NI may (at the 
dose used in vivo) also inhibits eNOS activity, which would in turn result in an increase in blood 
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pressure. This could explain the more pronounced effect of 7NI on mean arterial pressure. However, 
we have used 2 different nNOS inhibitors in order to reinforce our findings. The fact that 7NI may 
cause a weak inhibition of eNOS does not decrease the importance of our data, as i) ARL 17477 is a 
17-times more selective inhibitor of nNOS than eNOS (IC50 are 1 and 17 M, respectively); and ii) 
at the dose that we have chosen for our studies (1 mg/kg), the estimated plasma levels of ARL 17477 
are well below the IC50 for eNOS inhibition (16). Other non-specific effects are unlikely, as (a) we 
have used two potent and chemically distinct nNOS inhibitors, (b) both reduce nNOS activity in vivo 
at the doses used in our study (15, 18, 19), (c) both nNOS inhibitors show qualitatively and 
quantitatively similar beneficial effects in HS on a large number of parameters, (d) similar beneficial 
data with nNOS inhibitors in sepsis have been already confirmed with nNOS knockout animals and 
similar results were found (13).  
The fact that we have administered the nNOS inhibitors at the onset of resuscitation, and not 
prior to haemorrhage as performed by previous studies evaluating the iNOS role in HS (8), increases 
the clinical relevance of our findings. We believe that nNOS inhibitors could be employed as an 
adjunct therapy before the administration of fluids and blood in HS patients in order to avoid the 
MOF associated with reperfusion (during resuscitation).  
In conclusion, we show that the NO derived from nNOS has a harmful role, acting as a 
trigger for the initiation of the inflammatory response in HS. An enhanced formation of NO by 
nNOS is involved in the development of vascular dysfunction and MOF associated with HS. The 
organ protection observed in HS-rats treated with nNOS inhibitors was associated with reduction of 
neutrophil migration, attenuation of NF- B activation and consequently reduction of  systemic pro-
inflammatory cytokines TNF-  and IL-6, iNOS expression and nitrosylation of proteins by NO-
derived species. 
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FIGURE LEGENDS 
Figure 1. nNOS inhibition protects against multiple organ failure and dysfunction associated with 
HS. Rats were subjected to HS and received ARL 17477 (ARL), 7-nitroindazol (7NI) or vehicle at 
resuscitation. Four hours later, blood was obtained and serum creatinine (A), estimated creatinine 
clearance (B), serum aspartate aminotransferase (AST; C), serum alanine aminotransferase (ALT; 
D), serum creatine kinase (CK; E) and blood lactate (F) were determined. Sham animals were used 
as control. Data are expressed as mean ± SEM. Statistical analysis was performed using two-way 
*p<0.05 vs sham group and #p<0.05 vs HS group. 
Figure 2. nNOS inhibition attenuates cardiovascular dysfunction associated with HS. Rats were 
subjected to HS and received ARL 17477 (ARL), 7-nitroindazol (7NI) or vehicle at resuscitation. 
Sham animals were used as control. Panel A: The mean arterial pressure (MAP) of the animals was 
recorded during the whole experiment. Panel B: A dose-response curve of norepinephrine (1, 3 and 
10 nmol/kg; i.v.) was performed two hours after resuscitation. Data are expressed as mean ± SEM. 
Statistical analysis was performed using two-way ANO
*p<0.05 vs sham group and #p<0.05 vs HS group. 
Figure 3. nNOS inhibition attenuates neutrophils migration to kidney and liver in HS. Rats were 
subjected to HS and received ARL 17477 (ARL), 7-nitroindazol (7NI) or vehicle at resuscitation. 
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Sham animals were used as control. Immunostaining for myeloperoxidase (MPO) as a neutrophils 
marker was performed in kidney (Panel A) and liver (Panel B) tissue and the quantitative analysis of 
the number of cells / mm2 are shown. Data are expressed as mean ± SEM. Statistical analysis was 
performed using two- *p<0.05 vs sham group 
and #p<0.05 vs HS group. 
Figure 4. nNOS inhibition attenuates NF-  associated with HS. Rats were subjected to 
HS and received ARL 17477 (ARL), 7-nitroindazol (7NI) or vehicle at resuscitation. Sham animals 
were used as control. 32/36 (A and B) and the nuclear 
translocation of the p65 NF- C and D) on the kidney (A and C) and liver (B and D) were 
determined by western blotting. Protein expression was measured as relative optical density (O.D.), 
-actin contents and normalized using the related mean value of 
sham-operated band. Data are expressed as mean ± SEM. Statistical analysis was performed using 
one- *p<0.05 vs sham group and #p<0.05 vs 
HS group. 
Figure 5. nNOS inhibition attenuates the expression of inducible isoform of nitric oxide synthase 
(iNOS) in HS. Rats were subjected to HS and received ARL 17477 (ARL), 7-nitroindazol (7NI) or 
vehicle at resuscitation. Sham animals were used as control. The iNOS (A and B) and nNOS (C and 
D) expression in the kidney (A and C) and liver (B and D) were determined by western blotting. 
-
actin contents and normalized using the related mean value of sham-operated band. Data are 
expressed as mean ± SEM. Statistical analysis was performed using one-way ANOVA followed by 
*p<0.05 vs sham group and #p<0.05 vs HS group. 
Figure 6. nNOS inhibition attenuates serum nitrite + nitrate (NOx) in HS. Rats were subjected to HS 
and received ARL 17477 (ARL), 7-nitroindazol (7NI) or vehicle at resuscitation. Sham animals were 
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used as control. Serum NOx was determined through Griess reaction. Data are expressed as mean ± 
SEM. Statistical analysis was performed using two-
test. *p<0.05 vs sham group and #p<0.05 vs HS group. 
Figure 7. nNOS inhibition attenuates nitrotyrosine staining in kidney and liver in HS. Rats were 
subjected to HS and received ARL 17477 (ARL), 7-nitroindazol (7NI) or vehicle at resuscitation. 
Sham animals were used as control. Tyrosine nitration as an index of nitrosylation of proteins by 
peroxynitrite was determined by immunohistochemistry. The relative quantification of nitrotyrosine 
immunostaining was achieved through densitometry analysis and it is expressed as arbitrary units. 
Representative figures of kidney (A-F) and liver (Panel H-M) tissue and the quantitative analysis are 
shown (G and N). Data are expressed as mean ± SEM. Statistical analysis was performed using two-
*p<0.05 vs sham group and #p<0.05 vs HS 
group. 
Figure 8. nNOS inhibition attenuates serum inflammatory cytokines in HS. Rats were subjected to 
HS and received ARL 17477 (ARL), 7-nitroindazol (7NI) or vehicle at resuscitation. Sham animals 
were used as control. Serum concentrations of TNF- IL-6 (B) were determined. Data are 
expressed as mean ± SEM. Statistical analysis was performed using two-way ANOVA followed by 
*p<0.05 vs sham group and #p<0.05 vs HS group. 
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